Chitosan and poly(methyl vinyl ether-co-maleic anhydride) microparticles as nasal sustained delivery systems.
An original dosage form for nasal delivery based on the encapsulation of hydrophilic drug in chitosan-poly(methyl vinyl ether-co-maleic anhydride) (CH-PVM/MA) microparticles prepared by spray-drying technique was developed. Microparticles were characterized in terms of morphology, size, swelling properties, encapsulation efficiency and drug release. The physical state of the drug and the polymer was determined by scanning electron microscopy (SEM) and infrared spectroscopy (IR). Propranolol hydrochloride (PH) was a beta-blocker, used for the treatment of hypertension and was chosen as a model of hydrophilic drug. SEM studies showed spherical particles with smooth surfaces for chitosan hydrochloride (CH-HCl), whereas rather gross surface defects resulted from the incorporation of poly(methyl vinyl ether-co-maleic anhydride) (PVM/MA). In vitro release studies revealed a sustained release of propranolol HCl from microparticles and in particular chitosan hydrochloride provided the lowest release of drug.
Cerchiara
T
T
Department of Chemistry, Calabria University, Arcavacata di Rende (CS), Italy.
Luppi
B
B
Chidichimo
G
G
Bigucci
F
F
Zecchi
V
V
D000268:Adhesiveness; D000281:Administration, Intranasal; D048271:Chitosan / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D006863:Hydrogen-Ion Concentration; D008298:Maleates / Q000008:administration & dosage*; D008863:Microspheres; D011095:Polyethylenes / Q000008:administration & dosage*; D011433:Propranolol / Q000008:administration & dosage; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared
D008298:Maleates; D011095:Polyethylenes; C043105:poly(methyl vinyl ether-co-maleic anhydride); D048271:Chitosan; D011433:Propranolol